OLAGACT Trademark

Trademark Overview


On Thursday, June 17, 2021, a trademark application was filed for OLAGACT with the United States Patent and Trademark Office. The USPTO has given the OLAGACT trademark a serial number of 90779965. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Friday, April 5, 2024. This trademark is owned by Bristol-Myers Squibb Company. The OLAGACT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
olagact

General Information


Serial Number90779965
Word MarkOLAGACT
Filing DateThursday, June 17, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateFriday, April 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 27, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use in the nature of monoclonal antibodies for medical purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 19, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Saturday, April 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 5, 2024SOU EXTENSION 3 GRANTED
Friday, April 5, 2024SOU EXTENSION 3 FILED
Friday, April 5, 2024SOU TEAS EXTENSION RECEIVED
Thursday, November 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 29, 2023SOU EXTENSION 2 GRANTED
Friday, November 17, 2023SOU EXTENSION 2 FILED
Wednesday, November 29, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, November 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 17, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, May 2, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 28, 2023SOU EXTENSION 1 GRANTED
Friday, April 28, 2023SOU EXTENSION 1 FILED
Friday, April 28, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, November 22, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 27, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 27, 2022PUBLISHED FOR OPPOSITION
Wednesday, September 7, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, August 19, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 19, 2022EXAMINER'S AMENDMENT ENTERED
Friday, August 19, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, August 19, 2022EXAMINERS AMENDMENT E-MAILED
Friday, August 19, 2022EXAMINERS AMENDMENT -WRITTEN
Friday, August 12, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 12, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 12, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 15, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 15, 2022NON-FINAL ACTION E-MAILED
Tuesday, February 15, 2022NON-FINAL ACTION WRITTEN
Thursday, February 10, 2022ASSIGNED TO EXAMINER
Friday, September 3, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, June 21, 2021NEW APPLICATION ENTERED